Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cross-cultural development of a quality-of-life measure for patients with melanoma phase 3 testing of an EORTC Melanoma Module

Cross-cultural development of a quality-of-life measure for patients with melanoma phase 3... Original article 47 Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module a,b h a,b j,k Julie B. Winstanley , Teresa E. Young , Frances M. Boyle , Mia Bergenmar , l g m Andrew Bottomley , Bryan Burmeister , Luca G. Campana , i b,c n,o Jennifer J. Garioch , Madeleine King , Dejan V. Nikolic , p,q b,d b,d Lonneke V. van de Poll-Franse , Robyn Saw , John F. Thompson and e,f Edward G. White ; on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group Melanoma is an increasingly common skin cancer is planned and will be an important step forward in providing worldwide. Recent treatment advances have provided reliable QoL data to aid future decision-making in the patients and healthcare professionals (HCPs) with choices management and clinical trials of this complex group of where quality of life (QoL) and toxicity are important patients. Melanoma Res 25:47–58 Copyright © 2015 considerations. A melanoma-specific QoL questionnaire is Wolters Kluwer Health, Inc. All rights reserved. being developed in a cross-cultural setting using a four Melanoma Research 2015, 25:47–58 phase process developed http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Melanoma Research Wolters Kluwer Health

Cross-cultural development of a quality-of-life measure for patients with melanoma phase 3 testing of an EORTC Melanoma Module

Melanoma Research , Volume 25 (1) – Feb 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/cross-cultural-development-of-a-quality-of-life-measure-for-patients-Jf9gAx0NBw

References (37)

Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0960-8931
eISSN
1473-5636
DOI
10.1097/CMR.0000000000000122
pmid
25325247
Publisher site
See Article on Publisher Site

Abstract

Original article 47 Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module a,b h a,b j,k Julie B. Winstanley , Teresa E. Young , Frances M. Boyle , Mia Bergenmar , l g m Andrew Bottomley , Bryan Burmeister , Luca G. Campana , i b,c n,o Jennifer J. Garioch , Madeleine King , Dejan V. Nikolic , p,q b,d b,d Lonneke V. van de Poll-Franse , Robyn Saw , John F. Thompson and e,f Edward G. White ; on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group Melanoma is an increasingly common skin cancer is planned and will be an important step forward in providing worldwide. Recent treatment advances have provided reliable QoL data to aid future decision-making in the patients and healthcare professionals (HCPs) with choices management and clinical trials of this complex group of where quality of life (QoL) and toxicity are important patients. Melanoma Res 25:47–58 Copyright © 2015 considerations. A melanoma-specific QoL questionnaire is Wolters Kluwer Health, Inc. All rights reserved. being developed in a cross-cultural setting using a four Melanoma Research 2015, 25:47–58 phase process developed

Journal

Melanoma ResearchWolters Kluwer Health

Published: Feb 1, 2015

There are no references for this article.